Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChAd3-EBO-Z and MVA-BN-Filo in Healthy Adults
NCT03583606Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Nov 2018
- Primary completion
- Jan 2020
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cAd3-EBOV in Ebola Virus Disease (EVD), sponsored by National Institute of Allergy and Infectious Diseases. Started Nov 2018; status: completed.
02
Drugs
cAd3-EBOV
03
Conditions
Ebola Virus Disease (EVD)
Beyond the preview
Go deeper on NCT03583606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03583606.